Skip to main content
. 2023 Oct 28;143(6):496–506. doi: 10.1182/blood.2023021243

Figure 3.

Figure 3.

PFS of patients with FL based on the time point of bendamustine use before axi-cel infusion. Kaplan-Meier estimates of PFS among enrolled patients with FL by investigator assessment in those who had no prior bendamustine exposure, received bendamustine within 6 months of leukapheresis, received bendamustine between 6 and 12 months of leukapheresis, and received bendamustine >12 months before leukapheresis.